Status:
UNKNOWN
SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines
Lead Sponsor:
University Hospital, Tours
Collaborating Sponsors:
European Academy of Dermatology and Venerology
Conditions:
Merkel Cell Carcinoma
Eligibility:
All Genders
Phase:
NA
Brief Summary
Merkel cell carcinoma (MCC) is a rare aggressive skin carcinoma. Approximately 80% of MCC are related to the Merkel Cell Polyomavirus (MCPyV). Although rates of relapse are high, the follow-up strateg...
Eligibility Criteria
Inclusion
- Patients with a " de novo " diagnosis of MCC, confirmed on histological criteria (neuroendocrine morphology, CK20 staining and/or neuroendocrine and/or SATB2 staining, exclusion of differential diagnosis)
- ≥ 18 years of age
- Written informed consent obtained from the participant
Exclusion
- Patients following any measures of legal presentation
- Pregnancy or breastfeeding
Key Trial Info
Start Date :
September 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04705389
Start Date
September 1 2021
End Date
September 1 2023
Last Update
May 18 2021
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Dermatology, Medical University of Vienna
Vienna, Austria
2
University Hospital of Helsinki, Finland
Helsinki, Finland, 00100
3
Dermatology Dept, Hospital University of Tours
Tours, France, 37044
4
Translational Skin Cancer Research
Essen, Germany, 45141